Developer docs
API playgroundTry for free, no card

Search company profiles

Kallyope

Full company profile

uuid0000ey3

Namestring
Kallyope
Legal namestring
Kallyope Inc.
Websiteurl
kallyope.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Kallyope is a privately held, late-stage clinical biotechnology company founded in 2015 and headquartered in New York City, applying the science of gut-brain biology to develop therapeutics for migraine and metabolic disorders. Its integrated discovery engine, branded the Klarity™ Platform, combines single-cell transcriptional sequencing, neural circuit mapping via optogenetics and chemogenetics, proprietary human genetics derived from genome-wide association studies, mouse and human enteroid systems, and small-molecule and peptide chemistry capabilities to identify novel drug targets in neural circuits. The pipeline is anchored by elismetrep (K-304), a first-in-class oral TRPM8 antagonist for the acute treatment of migraine that has completed a positive Phase 2b study and is planned to enter Phase 3 in mid-2026, and by K-554, a first-in-class non-incretin peptide candidate for metabolic disease expected to enter Phase 1 in mid-2026.

Kallyope's commercial model today is bifurcated: future prescription pharmaceutical sales through standard wholesale, specialty pharmacy, and physician-prescribing channels post-FDA approval, and current non-dilutive income from licensing milestones and royalties. The September 2024 Novo Nordisk option exercise on an obesity ligand generated an upfront fee and entitles Kallyope to development and sales milestones plus worldwide royalties, while an $8.2 million Bill & Melinda Gates Foundation grant (May 2023) funds a separate environmental enteric dysfunction program. As of the latest disclosures, the company has raised approximately $479 million in total equity funding, including a $236 million Series D in February 2022 co-led by Mubadala Investment Company and The Column Group at a $1.446 billion post-money valuation, and has not yet reported commercial product revenue. The customer base, once products are approved, will be fragmented across migraine patients (one in six Americans) and metabolic/obesity patients (approximately one in three U.S. adults), targeted through traditional physician-led biopharmaceutical commercialization rather than direct-to-consumer channels.

Short descriptiontext

Kallyope is a late-stage clinical biotechnology company developing first-in-class gut-brain axis therapeutics, with elismetrep (a TRPM8 antagonist) entering Phase 3 for acute migraine and K-554 advancing into Phase 1 for metabolic disease, supported by the integrated Klarity™ discovery platform and a Novo Nordisk obesity partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gut-brain therapeutics, migraine drug development, metabolic disorder medicines, neural circuit drug discovery, biopharmaceutical pipeline
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical product sales
TypeOne Time License
Description

Kallyope is a late-stage biotechnology company developing novel therapeutics. Once drugs are approved by regulatory authorities (FDA and equivalent), the company will generate revenue through the sale of prescription pharmaceutical products, initially focusing on elismetrep for acute migraine treatment and K-554 for metabolic disease/obesity.

kallyope.com
2Licensing and milestone payments
TypeLicensing Royalties
Description

Kallyope has entered into licensing agreements with partners such as Novo Nordisk, receiving upfront option exercise fees and may receive additional payments for development and sales milestones and royalties on worldwide product sales of licensed products.

kallyope.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Klarity™ Platform
Description

An integrated end-to-end technology platform leveraging single-cell transcriptional sequencing, pathway circuit mapping, optogenetics and chemogenetics, proprietary validated human genetics, mouse and human organoids, and small molecules and peptides capabilities for drug discovery targeting neural circuits involved in migraine and metabolism.

kallyope.com
Core offering1 text field

Kallyope is a late-stage biotechnology company that discovers and develops novel therapeutics targeting the gut-brain axis. Its lead asset, elismetrep (K-304), is an oral TRPM8 antagonist in Phase 3 development for acute migraine, and its second program, K-554, is a non-incretin peptide for metabolic disorders entering Phase 1. Discovery is enabled by the proprietary Klarity™ Platform, which integrates single-cell sequencing, neural circuit mapping, optogenetics, human genetics, and organoid models to identify novel drug targets in neural circuits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2b: 20mg dose achieved 19.6% vs 9.1% placebo for 2h pain freedom (OR=2.4, P=0.0344), 38.3% vs 24.2% for freedom from most bothersome symptom (OR=1.9, P=0.0425), 58.8% vs 42.4% for pain relief (OR=1.9, P=0.0293)
+3 more records
Product overview1 text field

Kallyope is a late-stage biotechnology company developing innovative medicines for migraine and metabolic disorders. The company's portfolio includes two lead clinical programs: Elismetrep (K-304), a first-in-class oral TRPM8 antagonist for acute migraine treatment currently in Phase 2b and advancing toward pivotal studies in mid-2026, and K-554, a first-in-class non-incretin peptide for metabolic disease entering Phase 1 in mid-2026. The Klarity™ Platform serves as the core discovery engine, integrating single-cell sequencing, circuit mapping, optogenetics, human genetics, and organoid technologies to identify novel therapeutic targets in neural circuits. An undisclosed program is partnered with Novo Nordisk for obesity therapeutics.

Product and service4 records
1Elismetrep (K-304)
CategoryCore therapeutic product (small molecule)
Description

First-in-class oral antagonist of TRPM8 (Transient Receptor Potential Melastatin 8) being developed for the acute treatment of migraine. It is the only TRPM8 migraine-associated channel blocker in late-stage clinical development, targeting trigeminal sensory neurons via a mechanism distinct from CGRP antagonists and triptans, and has demonstrated efficacy and favorable safety/tolerability across 13 clinical studies with 1,055 people exposed.

2K-554
CategoryCore therapeutic product (peptide)
Description

First-in-class non-incretin peptide therapeutic candidate targeting a novel neural feeding circuit for metabolic disorders including obesity and type 2 diabetes. Distinct from GLP-1 and amylin receptor biology, it is intended to enable monotherapy and combination use with anticipated good tolerability. Entering clinical development in mid-2026.

3Klarity™ Platform
CategoryDrug discovery technology platform
Description

Integrated end-to-end discovery platform that combines single-cell transcriptional sequencing, pathway circuit mapping, optogenetics/chemogenetics, proprietary human genetics, mouse and human organoids, and small molecule/peptide capabilities to identify novel therapeutic targets in neural circuits. It is the core discovery engine that generated Kallyope's pipeline including elismetrep and K-554, and underpins the company's partnered discovery work with Novo Nordisk.

4Novo Nordisk Obesity Ligand Program
CategoryLicensed partnered program (peptide therapeutic for obesity)
Description

A Kallyope-discovered ligand licensed to Novo Nordisk for therapeutic development, including potential treatment for obesity. Novo Nordisk assumed responsibility for further preclinical and clinical development, manufacturing, and commercialization, with Kallyope retaining milestone and royalty economics.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-10
Description

Novo Nordisk exercised its option to license a Kallyope-identified ligand for therapeutic development including potential treatment for obesity. Under the terms of the research collaboration, Novo Nordisk will assume responsibility for further preclinical and clinical development, manufacturing, and commercialization. Kallyope received an upfront option exercise fee and may receive additional payments for development and sales milestones and royalties on worldwide product sales.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Acquired Allergan's migraine franchise including Ubrelvy (ubrogepant) for acute migraine and Qulipta (atogepant) for migraine prevention, both CGRP antagonists that compete directly with Kallyope's elismetrep. AbbVie is a much larger pharmaceutical incumbent with a broader diversified portfolio across immunology, oncology, and neuroscience.

TypeBroad incumbent
Description

Acquired Biohaven Pharmaceuticals in 2022 and now markets Nurtec ODT (rimegepant), a leading CGRP-targeting migraine therapy for both acute and preventive treatment, directly competing with elismetrep. Pfizer is a global pharmaceutical incumbent with a significantly broader portfolio across multiple therapeutic areas.

TypeBroad incumbent
Description

Markets Reyvow (lasmiditan), a 5-HT1F receptor agonist for acute migraine, and dominates the metabolic disease market with Mounjaro/Zepbound (tirzepatide) for obesity and type 2 diabetes. Lilly competes with Kallyope in both lead therapeutic areas as a much larger incumbent with significant commercial infrastructure.

TypeBroad incumbent
Description

Co-markets Aimovig (erenumab) with Novartis, the first-to-market CGRP receptor antibody for migraine prevention. Amgen is a large biotechnology incumbent with a broader portfolio across inflammation, oncology, and cardiovascular disease, competing with Kallyope's migraine program.

TypeBroad incumbent
Description

Markets Ajovy (fremanezumab), a CGRP antibody for migraine prevention. Teva is a global pharmaceutical incumbent with a broader portfolio including generics, central nervous system products, and immunology assets, competing in migraine prevention where elismetrep may eventually expand.

TypeBroad incumbent
Description

Markets Vyepti (eptinezumab), an IV-administered CGRP antibody for migraine prevention. Lundbeck is a mid-size pharmaceutical incumbent focused on neuroscience, directly competing with Kallyope in migraine with a focused but well-established commercial presence.

TypeDirect peer
Description

Late-stage clinical biotechnology company developing VK2735, a dual GLP-1/GIP receptor agonist in Phase 2/3 for obesity, and VK2809 for metabolic liver disease. Highly comparable to Kallyope's metabolic program given similar company size, clinical stage, and therapeutic focus in obesity and metabolic disorders.

TypeDirect peer
Description

Clinical-stage biotechnology company developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and metabolic liver disease. Similar company size and stage as Kallyope with overlapping metabolic disease focus and comparable clinical milestones.

TypeDirect peer
Description

Clinical-stage biotechnology company developing oral small molecule GLP-1 agonists and other peptide-based therapies for metabolic diseases and pulmonary hypertension. Directly comparable to Kallyope's peptide approach in metabolic disease with similar company size and development stage.

TypeDirect peer
Description

Late-stage CNS-focused biotechnology company with Auvelity (dextromethorphan-bupropion) for major depressive disorder and AXS-07 (MoSEIC meloxicam-rizatriptan) for acute migraine. Comparable size, clinical stage, and CNS drug development focus to Kallyope with similar investor profile and pre-commercial business model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kallyope

Biopharmaceutical Therapeuticskallyope.com

Kallyope is a late-stage clinical biotechnology company developing first-in-class gut-brain axis therapeutics, with elismetrep (a TRPM8 antagonist) entering Phase 3 for acute migraine and K-554 advancing into Phase 1 for metabolic disease, supported by the integrated Klarity™ discovery platform and a Novo Nordisk obesity partnership.

What Kallyope does

Kallyope is a privately held, late-stage clinical biotechnology company founded in 2015 and headquartered in New York City, applying the science of gut-brain biology to develop therapeutics for migraine and metabolic disorders. Its integrated discovery engine, branded the Klarity™ Platform, combines single-cell transcriptional sequencing, neural circuit mapping via optogenetics and chemogenetics, proprietary human genetics derived from genome-wide association studies, mouse and human enteroid systems, and small-molecule and peptide chemistry capabilities to identify novel drug targets in neural circuits. The pipeline is anchored by elismetrep (K-304), a first-in-class oral TRPM8 antagonist for the acute treatment of migraine that has completed a positive Phase 2b study and is planned to enter Phase 3 in mid-2026, and by K-554, a first-in-class non-incretin peptide candidate for metabolic disease expected to enter Phase 1 in mid-2026.

Kallyope's commercial model today is bifurcated: future prescription pharmaceutical sales through standard wholesale, specialty pharmacy, and physician-prescribing channels post-FDA approval, and current non-dilutive income from licensing milestones and royalties. The September 2024 Novo Nordisk option exercise on an obesity ligand generated an upfront fee and entitles Kallyope to development and sales milestones plus worldwide royalties, while an $8.2 million Bill & Melinda Gates Foundation grant (May 2023) funds a separate environmental enteric dysfunction program. As of the latest disclosures, the company has raised approximately $479 million in total equity funding, including a $236 million Series D in February 2022 co-led by Mubadala Investment Company and The Column Group at a $1.446 billion post-money valuation, and has not yet reported commercial product revenue. The customer base, once products are approved, will be fragmented across migraine patients (one in six Americans) and metabolic/obesity patients (approximately one in three U.S. adults), targeted through traditional physician-led biopharmaceutical commercialization rather than direct-to-consumer channels.

Kallyope firmographics

Firmographics
Name
Kallyope
Legal name
Kallyope Inc.
Website
https://kallyope.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Kallyope is a late-stage clinical biotechnology company developing first-in-class gut-brain axis therapeutics, with elismetrep (a TRPM8 antagonist) entering Phase 3 for acute migraine and K-554 advancing into Phase 1 for metabolic disease, supported by the integrated Klarity™ discovery platform and a Novo Nordisk obesity partnership.
Ownership category
akta.pro rank

Kallyope industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Gut-brain therapeutics
  • Migraine drug development
  • Metabolic disorder medicines
  • Neural circuit drug discovery
  • Biopharmaceutical pipeline

Where Kallyope is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kallyope business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical product sales: Kallyope is a late-stage biotechnology company developing novel therapeutics. Once drugs are approved by regulatory authorities (FDA and equivalent), the company will generate revenue through the sale of prescription pharmaceutical products, initially focusing on elismetrep for acute migraine treatment and K-554 for metabolic disease/obesity.
  2. Licensing and milestone payments: Kallyope has entered into licensing agreements with partners such as Novo Nordisk, receiving upfront option exercise fees and may receive additional payments for development and sales milestones and royalties on worldwide product sales of licensed products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Kallyope product offering

Product offering

Core offering

Kallyope is a late-stage biotechnology company that discovers and develops novel therapeutics targeting the gut-brain axis. Its lead asset, elismetrep (K-304), is an oral TRPM8 antagonist in Phase 3 development for acute migraine, and its second program, K-554, is a non-incretin peptide for metabolic disorders entering Phase 1. Discovery is enabled by the proprietary Klarity™ Platform, which integrates single-cell sequencing, neural circuit mapping, optogenetics, human genetics, and organoid models to identify novel drug targets in neural circuits.

Product overview

Kallyope is a late-stage biotechnology company developing innovative medicines for migraine and metabolic disorders. The company's portfolio includes two lead clinical programs: Elismetrep (K-304), a first-in-class oral TRPM8 antagonist for acute migraine treatment currently in Phase 2b and advancing toward pivotal studies in mid-2026, and K-554, a first-in-class non-incretin peptide for metabolic disease entering Phase 1 in mid-2026. The Klarity™ Platform serves as the core discovery engine, integrating single-cell sequencing, circuit mapping, optogenetics, human genetics, and organoid technologies to identify novel therapeutic targets in neural circuits. An undisclosed program is partnered with Novo Nordisk for obesity therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • Klarity™ Platform: An integrated end-to-end technology platform leveraging single-cell transcriptional sequencing, pathway circuit mapping, optogenetics and chemogenetics, proprietary validated human genetics, mouse and human organoids, and small molecules and peptides capabilities for drug discovery targeting neural circuits involved in migraine and metabolism.

Products and services

  • Elismetrep (K-304) First-in-class oral antagonist of TRPM8 (Transient Receptor Potential Melastatin 8) being developed for the acute treatment of migraine. It is the only TRPM8 migraine-associated channel blocker in late-stage clinical development, targeting trigeminal sensory neurons via a mechanism distinct from CGRP antagonists and triptans, and has demonstrated efficacy and favorable safety/tolerability across 13 clinical studies with 1,055 people exposed.
  • K-554 First-in-class non-incretin peptide therapeutic candidate targeting a novel neural feeding circuit for metabolic disorders including obesity and type 2 diabetes. Distinct from GLP-1 and amylin receptor biology, it is intended to enable monotherapy and combination use with anticipated good tolerability. Entering clinical development in mid-2026.
  • Klarity™ Platform Integrated end-to-end discovery platform that combines single-cell transcriptional sequencing, pathway circuit mapping, optogenetics/chemogenetics, proprietary human genetics, mouse and human organoids, and small molecule/peptide capabilities to identify novel therapeutic targets in neural circuits. It is the core discovery engine that generated Kallyope's pipeline including elismetrep and K-554, and underpins the company's partnered discovery work with Novo Nordisk.
  • Novo Nordisk Obesity Ligand Program A Kallyope-discovered ligand licensed to Novo Nordisk for therapeutic development, including potential treatment for obesity. Novo Nordisk assumed responsibility for further preclinical and clinical development, manufacturing, and commercialization, with Kallyope retaining milestone and royalty economics.

Quantifiable outcome

  • Phase 2b: 20mg dose achieved 19.6% vs 9.1% placebo for 2h pain freedom (OR=2.4, P=0.0344), 38.3% vs 24.2% for freedom from most bothersome symptom (OR=1.9, P=0.0425), 58.8% vs 42.4% for pain relief (OR=1.9, P=0.0293)
  • +3 more outcomes

Companies that use Kallyope

Customer profile

Segments2 records

Ideal customer profiles3 records

Kallyope technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Kallyope partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Novo NordiskflagshipStrategic or Co-development Partner · 10 September 2024Novo Nordisk exercised its option to license a Kallyope-identified ligand for therapeutic development including potential treatment for obesity. Under the terms of the research collaboration, Novo Nordisk will assume responsibility for further preclinical and clinical development, manufacturing, and commercialization. Kallyope received an upfront option exercise fee and may receive additional payments for development and sales milestones and royalties on worldwide product sales.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Kallyope competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Acquired Allergan's migraine franchise including Ubrelvy (ubrogepant) for acute migraine and Qulipta (atogepant) for migraine prevention, both CGRP antagonists that compete directly with Kallyope's elismetrep. AbbVie is a much larger pharmaceutical incumbent with a broader diversified portfolio across immunology, oncology, and neuroscience.
  • Pfizer: Acquired Biohaven Pharmaceuticals in 2022 and now markets Nurtec ODT (rimegepant), a leading CGRP-targeting migraine therapy for both acute and preventive treatment, directly competing with elismetrep. Pfizer is a global pharmaceutical incumbent with a significantly broader portfolio across multiple therapeutic areas.
  • Eli Lilly: Markets Reyvow (lasmiditan), a 5-HT1F receptor agonist for acute migraine, and dominates the metabolic disease market with Mounjaro/Zepbound (tirzepatide) for obesity and type 2 diabetes. Lilly competes with Kallyope in both lead therapeutic areas as a much larger incumbent with significant commercial infrastructure.
  • Amgen: Co-markets Aimovig (erenumab) with Novartis, the first-to-market CGRP receptor antibody for migraine prevention. Amgen is a large biotechnology incumbent with a broader portfolio across inflammation, oncology, and cardiovascular disease, competing with Kallyope's migraine program.
  • Teva Pharmaceutical Industries: Markets Ajovy (fremanezumab), a CGRP antibody for migraine prevention. Teva is a global pharmaceutical incumbent with a broader portfolio including generics, central nervous system products, and immunology assets, competing in migraine prevention where elismetrep may eventually expand.
  • Lundbeck: Markets Vyepti (eptinezumab), an IV-administered CGRP antibody for migraine prevention. Lundbeck is a mid-size pharmaceutical incumbent focused on neuroscience, directly competing with Kallyope in migraine with a focused but well-established commercial presence.

Direct peers

  • Viking Therapeutics: Late-stage clinical biotechnology company developing VK2735, a dual GLP-1/GIP receptor agonist in Phase 2/3 for obesity, and VK2809 for metabolic liver disease. Highly comparable to Kallyope's metabolic program given similar company size, clinical stage, and therapeutic focus in obesity and metabolic disorders.
  • Altimmune: Clinical-stage biotechnology company developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and metabolic liver disease. Similar company size and stage as Kallyope with overlapping metabolic disease focus and comparable clinical milestones.
  • Structure Therapeutics: Clinical-stage biotechnology company developing oral small molecule GLP-1 agonists and other peptide-based therapies for metabolic diseases and pulmonary hypertension. Directly comparable to Kallyope's peptide approach in metabolic disease with similar company size and development stage.
  • Axsome Therapeutics: Late-stage CNS-focused biotechnology company with Auvelity (dextromethorphan-bupropion) for major depressive disorder and AXS-07 (MoSEIC meloxicam-rizatriptan) for acute migraine. Comparable size, clinical stage, and CNS drug development focus to Kallyope with similar investor profile and pre-commercial business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Kallyope social profiles

Digital presence

Kallyope financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kallyope leadership team

Management profile

Number of profiles

Profiles12 records

Kallyope funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kallyope M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kallyope

What does Kallyope do?

Kallyope is a late-stage biotechnology company that discovers and develops novel therapeutics targeting the gut-brain axis. Its lead asset, elismetrep (K-304), is an oral TRPM8 antagonist in Phase 3 development for acute migraine, and its second program, K-554, is a non-incretin peptide for metabolic disorders entering Phase 1. Discovery is enabled by the proprietary Klarity™ Platform, which integrates single-cell sequencing, neural circuit mapping, optogenetics, human genetics, and organoid models to identify novel drug targets in neural circuits.

Is Kallyope a public or private company?

Kallyope is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kallyope founded?

Kallyope was founded in 2015. It employs 11 to 50 people.

Where is Kallyope based?

Kallyope is headquartered in New York, United States, in the North America region.

How does Kallyope make money?

Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are licensing and milestone payments.

Who are Kallyope's main competitors?

Broad incumbents on record are AbbVie, Pfizer, Eli Lilly, Amgen, Teva Pharmaceutical Industries and Lundbeck. Direct peers are Viking Therapeutics, Altimmune, Structure Therapeutics and Axsome Therapeutics.

Does Kallyope have an API?

No public API is recorded for Kallyope.

What industry is Kallyope in?

Kallyope's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumSpace pharma Varda raises $251m, and other financingsVarda Space Industries closed a $251 million Series D round to fund orbital pharmaceutical manufacturing, led by Lux Capital and Natural Capital. The company claims to be the only one with six successful launches and re-entry missions. Other biotechs also raised funds this week, including Kallyope's $94 million and Breye Therapeutics' €67.5 million.Endpoints NewsExclusive: After Novo obesity deal, Kallyope rebrands and gets $94M for migraine trialsKallyope, a New York City drug developer, is rebranding as TriGemX Bio to focus solely on migraine treatment. The company has secured $94 million for migraine trials to support the restructured business.BioSpaceNovo buys three early-stage obesity assets from Kallyope as investor pressure mountsNovo acquired three early-stage obesity assets from Kallyope, including a peptide therapy K-554 ready for an investigational new drug application. The deal aims to expand beyond GLP-1s, as Novo faces investor pressure to strengthen its pipeline amid semaglutide patent expirations.The Pharma LetterNovo buys three non-incretin obesity programs from KallyopeNovo acquired three early-stage obesity programs from Kallyope via an asset purchase agreement disclosed on Friday. The programs use non-incretin approaches, distinct from GLP-1 medicines like Wegovy, to hedge against nausea and weight regain. The acquisition aims to widen patient options.FierceBiotechRefreshed Novo corrals 3 new early-stage obesity drugs from KallyopeNovo Nordisk acquired three obesity programs from Kallyope, including a lead peptide candidate K-554 that is IND-ready. The company expects phase 1 data for K-554 in the second half of 2026. The deal follows Novo's recent brand refresh and a $1.4 billion pact with Orbis Medicines.Patient Care OnlineKallyope's Oral TRPM8 Antagonist Advances Toward Registrational Studies for Acute Migraine TreatmentKallyope reported favorable top-line results from a phase 2b trial of its investigational oral TRPM8 antagonist, elismetrep, for the acute treatment of migraine. The study enrolled 431 US adults and demonstrated a competitive clinical profile with no significant safety signals, supporting the drug's potential to address unmet needs in patients who do not respond to existing therapies. Kallyope plans to initiate registrational studies in mid-2026 following recent pipeline setbacks.Neurology liveInvestigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute MigraineKallyope announced positive results from its phase 2b study of elismetrep, an investigational TRPM8 antagonist for the acute treatment of migraine. The double-blind, placebo-controlled trial involving 431 participants in the United States demonstrated that elismetrep achieved efficacy endpoints comparable to marketed therapies with a favorable safety profile. The company plans to initiate registrational studies in 2026.The Pharma LetterKallyope advances elismetrep after mid-stage migraine winKallyope announced positive results from a Phase IIb study of its oral migraine candidate elismetrep, prompting plans to advance the drug toward registrational development. The company intends to begin pivotal studies in mid-2026 following this favorable clinical profile. This progress comes after the company recently halted a separate migraine trial and pivoted focus away from disappointing weight-loss programs.BioSpaceKallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific MeetingKallyope presented new clinical and preclinical data on elismetrep, a TRPM8 channel blocker for migraine, highlighting a novel formulation that enables faster absorption compared to previous versions. The company announced that Phase 3 studies for the drug are anticipated to initiate in mid-2026.Business Wire BlogKallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific MeetingKallyope presented clinical and preclinical data for its novel TRPM8 channel blocker elismetrep at the American Headache Society 68th Annual Scientific Meeting in Orlando, Florida, supporting the advancement of the drug into Phase 3 trials anticipated to begin in mid-2026. A new liquid-filled softgel capsule formulation demonstrated accelerated absorption with a median time to maximum concentration of 1 hour compared to 2.5 hours for the earlier dry-filled capsule formulation, with model-based simulations predicting approximately 50% and 40% improvements in placebo-corrected response rates for 2-hour pain freedom and 2-hour freedom from the most bothersome migraine symptom, respectively. Preclinical studies also showed additive efficacy when elismetrep was combined with gepants or triptans, suggesting potential for combination therapy.